Cyclopentyl modulators of chemokine receptor activity

1. A compound of Formula (I):

or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein:

D and G are defined as follows:

(A) D is —H and G is

(B) D is R 7 and G is

 or

(C) D is R 15 and G is R 1 ;

(D) D is —H and G is

 or

(E) D and G together form

R 1 is:

(1) —CO 2 H,

(2) —C(═O)NR y R z ,

(3) tetrazolyl,

(4) —SO 2 NHCO—R u , or

(5) —P(O)(OH) 2 ;

R 2 is:

R 3 is phenyl which is optionally substituted with from 1 to 5 substituents each of which is independently:

(a) halo,

(b) —C 1-3 haloalkyl,

(c) —OH,

(d) —C 1-3 alkyl,

(e) —O—C 1-3 alkyl,

(f) —CO 2 R u ,

(g) —NR u R v , or

(h) —C(═O)NR u R v ;

R 4 , R 5 and R 6 are defined as follows:

(A) each of R 4 , R 5 and R 6 is independently —H, —C 1-10 alkyl, —C 3-8 cycloalkyl, —C 2-10 alkenyl, —C 2-10 alkynyl, phenyl, —C 1-6 alkyl-phenyl, —C 1-6 alkyl-C 3-8 cycloalkyl, naphthyl, or biphenyl; and wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, cycloalkylalkyl, naphthyl, or biphenyl, is optionally subsituted with from 1 to 5 substituents each of which is independently:

(a) halo,

(b) —C 1-3 haloalkyl,

(c) —OH,

(d) —C 1-3 alkyl,

(e) —O—C 1-3 alkyl,

(f) —CO 2 R u ,

(g) —NR u R v , or

(h) —C(═O)NR u R v ; or

(B) with the proviso that n is 1, R 6 is as defined in (A); and R 4 and R 5 are joined together to form with the carbon atom to which both are attached a 3- to 8-membered saturated carbocyclic ring which is optionally substituted with from 1 to 5 substituents each of which is independently:

(a) halo,

(b) —C 1-3 haloalkyl,

(c) —OH,

(d) —C 1-3 alkyl,

(e) —O—C 1-3 alkyl,

(f) —CO 2 R u ,

(g) —NR u R v , or

(h) —C(═O)NR u R v ;

R 7 is —H or —C 1-6 alkyl;

R 8 is —H or —C 1-6 alkyl;

R 9 is —NR s R t ,

R 14 is —H or —C 1-10 alkyl;

R 15 is —H, —NR s R t , —C 1-10 alkyl, —C 2-10 alkenyl, —C 3-8 cycloalkyl, —C 5-8 cycloalkenyl, or —C 1-6 alkyl-C 3-8 cycloalkyl; wherein the alkyl, alkenyl, cycloalkyl, cycloalkenyl, or the cycloalkylalkyl is optionally subsituted with from 1 to 5 substituents each of which is independently:

(a) halo,

(b) —C 1-3 haloalkyl,

(c) —OH,

(d) —C 1-3 alkyl, or

(e) —O—C 1-3 alkyl;

R s and R t are each independently —H, —C 1-6 alkyl, or —C 1-6 alkyl-C 3-8 cycloalkyl;

each R u is independently —H, —C 1-6 alkyl, —C 5-6 cycloalkyl, benzyl or phenyl, wherein the alkyl, cycloalkyl, benzyl, or phenyl is optionally substituted with from 1 to 3 substituents each of which is independently halo, —C 1-3 alkyl, —O—C 1-3 alkyl, or —C 1-3 haloalkyl;

each R v is independently —H, —C 1-6 alkyl, —C 5-6 cycloalkyl, benzyl or phenyl, wherein the alkyl, cycloalkyl, benzyl, or phenyl is optionally substituted with from 1 to 3 substituents each of which is independently halo, —C 1-3 alkyl, —O—C 1-3 alkyl, or —C 1-3 haloalkyl;

each R w is independently —H, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or —C 1-6 alkyl-aryl; wherein the aryl in the arylalkyl group is optionally substituted with from 1 to 5 substituents each of which is independently halo, —C 1-6 alkyl, or —O—C 1-6 alkyl;

R x is —H, —C 1-6 alkyl, —C 1-6 haloalkyl, or —C 1-6 alkyl-aryl; wherein the aryl in the arylalkyl group is optionally substituted with from 1 to 5 substituents each of which is independently halo, —C 1-6 alkyl, or —O—C 1-6 alkyl;

R y and R z are each independently —H or —C 1-6 alkyl; and

n is an integer which is equal to 1, 2, 3, or 4.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 1 is —CO 2 H, —C(═O)NR y R z , or tetrazolyl.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 1 is —CO 2 H or —C(═O)NH 2 .

4. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 1 is —CO 2 H.

5. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 2 is:

6. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 2 is:

7. The compound according to claim 6 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein:

R w is —H, —C 1-4 alkyl, —C 1-4 fluoroalkyl, —O—C 1-4 alkyl, —O—C 1-4 fluoroalkyl, or —C 1-3 alkyl-phenyl; wherein the phenyl in the phenylalkyl group is optionally substituted with from 1 to 4 substituents each of which is independently halo, —C 1-4 alkyl, or —O—C 1-4 alkyl; and

R x is —H, —C 1-4 alkyl, —C 1-4 fluoroalkyl, or —C 1-3 alkyl-phenyl; wherein the phenyl in phenylalkyl group is optionally substituted with from 1 to 4 substituents each of which is independently halo, —C 1-4 alkyl, or —O—C 1-4 alkyl.

8. The compound according to claim 7 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein:

R w is —H, —C 1-3 alkyl, —CF 3 , —O—C 1-3 alkyl, —O—CF 3 , or benzyl; wherein the benzyl ring is optionally substituted with from 1 to 3 substituents each of which is independently bromo, chloro, fluoro, —C 1-3 alkyl, or —O—C 1-3 alkyl; and

R x is —H, —C 1-3 alkyl, or —CF 3 .

9. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 3 is phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently:

(a) halo,

(b) —C 1-3 fluoroalkyl,

(c) —OH,

(d) —C 1-3 alkyl, or

(e) —O—C 1-3 alkyl.

10. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 3 is phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently:

(a) halo,

(b) —CF 3 ,

(c) —OH,

(d) —C 1-3 alkyl, or

(e) —O—C 1-3 alkyl.

11. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 3 is phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently:

(a) fluoro,

(b) chloro,

(c) —CF 3 ,

(d) —OH, or

(e) —C 1-3 alkyl.

12. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 3 is phenyl opitionally substituted with from 1 to 4 substituents each of which is independently fluoro or chloro.

13. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 3 is phenyl, 3-fluorophenyl, 3,4-difluorophenyl, or 3,5-difluorophenyl.

14. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 8 is —H or —CH 3 .

15. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 8 is —H.

16. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, wherein R 15 is —NR s R t , —C 1-10 alkyl, or —C 1-6 alkyl-C 3-8 cycloalkyl; wherein the alkyl or the cycloalkylalkyl is optionally subsituted with from 1 to 5 substituents each of which is independently:

(a) halo,

(b) —C 1-3 haloalkyl,

(c) —OH,

(d) —C 1-3 alkyl, or

(e) —O—C 1-3 alkyl.

17. The compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, which is a compound of Formula XA or XB:

18. A compound selected from the group consisting of

N-methyl-N-(1-(R)-3-(S)-((2′-benzyl-5′,6′-dihydrospiro[piperidin-1-yl-4,4′-[4H]pyrrolo[1,2-b]pyrazole])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((2-ethyl-5,6 dihydrospiro[cyclopentapyrazole-4(2H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((2,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(2H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1-ethyl-5,6 dihydrospiro[cyclopentapyrazole-4(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1-ethyl-3-methyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-dimethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((3-methyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((2,3-diethyl-5,6 dihydrospiro[cyclopentapyrazole-4(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-5,6 dihydrospiro[cyclopentapyrazole-4(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((3-ethyl-1-methyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R,S)-α-methylvaline;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-leucine;

N-ethyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4 ′-piperidin-1′-yl])methyl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3,4-difluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1-ethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1-methyl-3-ethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(R)-3-(S)-((3-ethyl-1-methyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((3-ethyl-4,5-dihydrospiro[6H-cyclopent[d]isoxazole-6,4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((3-ethyl-4,5-dihydrospiro[6H-cyclopent[c]isoxazole-6,4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1-ethyl-3-methoxy-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((2-ethyl-3-methoxy-4,5-dihydrospiro[cyclopentapyrazole-6(2H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluoro-4-methylphenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3,4-dichlorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(4-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1-ethyl-3-methoxy-5,6-dihydrospiro[cyclopenta-pyrazole-4(2H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((2-ethyl-3-methoxy-5,6-dihydrospiro[cyclopenta-pyrazole-4(2H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1-methyl-3-methoxy-4,5-dihydrospiro[cyclopenta-pyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1-ethyl-3-methoxy-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(R)-3-(S)-((3-ethyl-1-methyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(R)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(S)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(S)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(R)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(S)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(S)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3,5-difluorophenyl)cyclopent-1-yl)-(R)-t-butylglycine;

N-methyl-N-(1-(R)-methyl-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(S)-methyl-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-(1-(R)-methyl-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-(1-(S)-methyl-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R,S)-α-methylvaline;

N-(1-(S)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R,S)-α-methylvaline;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valinamide;

N-methyl-N-(1-(S)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valinamide;

N-methyl-N-(1-(R)-3-(S)-((2′-ethyl-5′,6′-dihydrospiro[piperidin-1-yl-4,4′-[4H]pyrrolo[1,2-b]pyrazole])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((1,3-diethyl-4,6-dihydrospiro[furo[3,4-c]pyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

N-methyl-N-(1-(R)-3-(S)-((2,3-diethyl-4,6-dihydrospiro[furo[3,4-c]pyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-(R)-valine;

2-(S)-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-2-(1,1-dimethylprop-1-ylamino)acetic acid;

2-(S)-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-2-((1,1-dimethylprop-1-yl)methylamino)acetic acid;

2-(S)-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-3-(cyclopropyl)propionic acid;

2-(R)-(1-(R)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)-3-(cyclopropyl)propionic acid;

1-(R or S)-(2,2-dimethylprop-1-ylamino)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopentane carboxylic acid;

1-(R or S)-((2,2-dimethylprop-1-yl)methylamino)-3-(S)-((1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])methyl)-4-(S)-(3-fluorophenyl)cyclopentane carboxylic acid;

1-(S)-((2,2-dimethylprop-1-yl)amino)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3-fluorophenyl)cyclopentane carboxylic acid;

1-(R)-((2,2-dimethylprop-1-yl)amino)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3-fluorophenyl)cyclopentane carboxylic acid;

1-(R)-(dimethylamino)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3-fluorophenyl)cyclopentane carboxylic acid;

1-(S)-(dimethylamino)-3-(S)-(1-(R)-(1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4′-piperidin-1′-yl])eth-1-yl)-4-(S)-(3-fluorophenyl)cyclopentane carboxylic acid;

and pharmaceutically acceptable salts thereof.

19. A pharmaceutical composition which comprises an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof, and a pharmaceutically acceptable carrier.

20. A method for treating infection by HIV, delaying of the onset of AIDS, or inhibit progression to AIDS in a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt and/or an individual diastereomer thereof.